Inhibikase Therapeutics, Inc. Quarterly Depreciation in USD from Q1 2022 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Inhibikase Therapeutics, Inc. quarterly/annual Depreciation history and growth rate from Q1 2022 to Q3 2024.
  • Inhibikase Therapeutics, Inc. Depreciation for the quarter ending September 30, 2024 was $6.57K, unchanged year-over-year.
  • Inhibikase Therapeutics, Inc. Depreciation for the twelve months ending September 30, 2024 was $26.3K, a 85.1% decline year-over-year.
  • Inhibikase Therapeutics, Inc. annual Depreciation for 2023 was $177K, a 2539% increase from 2022.
  • Inhibikase Therapeutics, Inc. annual Depreciation for 2022 was $6.72K.
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $26.3K $6.57K $0 0% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $26.3K $6.57K -$153K -95.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $179K $6.57K +$1.53K +30.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $177K $6.58K +$1.54K +30.6% Oct 1, 2023 Dec 31, 2023 10-Q 2024-05-15
Q3 2023 $176K $6.57K +$4.89K +291% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 $171K $159K +$159K Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $11.8K $5.04K +$5.04K Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $6.72K $5.04K Oct 1, 2022 Dec 31, 2022 10-K 2024-03-27
Q3 2022 $1.68K Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $0 Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $0 Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.